SCHEMBL6488927

SCHEMBL6488927

Cc1cc(-c2cccc(C(=O)O)c2)cc2c1nc(C)n2Cc1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.44
GLA P06280 2/20 0.41
HPGD P15428 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
EIF4EBP1 Q13541 6/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 1/20 0.38
DCTPP1 Q9H773 1/20 0.38
GRIN2B Q13224 1/20 0.38
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490617 0.91 DCTPP1 (0.43) MRGPRX4GLAHPGDTRPM8KMT2A
SCHEMBL6488962 0.89 MRGPRX4 (0.41) MRGPRX4GLAHPGDTRPM8KMT2A
SCHEMBL6487328 0.89 RXRA (0.40) MRGPRX4EIF4EBP1DCTPP1
SCHEMBL6496043 0.88 MRGPRX4 (0.45) MRGPRX4GLAHPGDTRPM8KMT2A
SCHEMBL6502236 0.86 MRGPRX4 (0.39) MRGPRX4GLAHPGDKMT2AMEN1
SCHEMBL6498752 0.82 MEN1 (0.41) HPGDKMT2AMEN1CYP1A2CYP3A4
SCHEMBL7195728 0.82 CYP1A2 (0.38) GLAHPGDKMT2AMEN1RAB9A
SCHEMBL7199966 0.82 CYP1A2 (0.38) GLAHPGDKMT2AMEN1RAB9A
SCHEMBL6489988 0.80 DCTPP1 (0.40) MRGPRX4GLAHPGDKMT2AMEN1
SCHEMBL6490408 0.80 JMJD6 (0.41) HPGDKMT2AMEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MRGPRX4 2443/4885GLA 711/4885HPGD 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.